Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP28 | Q96RU2 | 8/20 | 0.67 |
| ▸ | USP25 | Q9UHP3 | 5/20 | 0.66 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890911 | 0.91 | USP28 (0.66) | USP28USP25CHRM4LMNANPC1 | |
| SCHEMBL4898867 | 0.91 | USP28 (0.73) | USP28USP25CHRM4LMNANPC1 | |
| SCHEMBL4898520 | 0.91 | USP28 (0.72) | USP28USP25CHRM4LMNANPC1 | |
| SCHEMBL4887005 | 0.89 | USP28 (0.64) | USP28USP25CHRM4LMNANPC1 | |
| SCHEMBL27708055 | 0.89 | USP28 (0.73) | USP28USP25CHRM4LMNANPC1 | |
| SCHEMBL4888275 | 0.88 | USP28 (0.74) | USP28USP25CHRM4LMNANPC1 | |
| SCHEMBL4897966 | 0.87 | USP28 (0.70) | USP28USP25CHRM4LMNANPC1 | |
| SCHEMBL4894197 | 0.86 | USP28 (0.67) | USP28USP25CHRM4LMNANPC1 | |
| SCHEMBL4896784 | 0.85 | USP28 (0.71) | USP28USP25CHRM4LMNANPC1 | |
| SCHEMBL4897949 | 0.85 | CHRM4 (0.64) | USP28USP25CHRM4LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306107-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| CN-101128470-A | Novel compounds | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | CN | claimed |
| US-20080306107-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| CN-101128470-A | Novel compounds | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306107-A1 | Compounds | FURIN, PCSK9, SLC10A1 | USP28 4875/4885USP25 4874/4885CHRM4 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.